Johnson & Johnson Receives FDA Approval for Non-Small Cell Lung Cancer Treatments
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) have been FDA-approved as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. The Phase 3 MARIPOSA study showed a 30% reduction in disease progression risk with this combination, providing a significant new option for patients.
Johnson & Johnson Receives FDA Approval for Non-Small Cell Lung Cancer Treatments